ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: L09 • ACR Convergence 2024

    Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

    Hermine Brunner1, Caifeng Li2, Kogie Chinniah3, Yosef Uziel4, Olga Synoverska5, Sujata Sawhney6, Inmaculada Calvo Penades7, Ingrid Clara Louw8, Meiping Lu9, Pooja Nikunj Patel10, Pamela F. Weiss11, Cheng Chang12, Ivana Vranic13, Shixue Liu14, Annette Diehl15, Jose L. Rivas16, Carol A. Connell17, Gary G. Koch18, Alberto Martini19, Daniel J. Lovell1, Nicolino Ruperto20 and the PRINTO and PRCSG investigators, 1Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, 2Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, 3Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, 4Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, 5Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, 6Sir Ganga Ram Hospital, New Delhi, India, 7Hospital Universitario y Politécnico La Fe, Valencia, Spain, 8Panorama Medical Centre, Cape Town, South Africa, 9Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 10Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, 11Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13Pfizer Ltd, Tadworth, United Kingdom, 14Pfizer Inc, Shanghai, China, 15Pfizer Inc, Collegeville, PA, 16Pfizer SLU, Madrid, Spain, 17Pfizer Inc, Groton, CT, 18University of North Carolina at Chapel Hill, Chapel Hill, NC, 19University of Genoa, Genoa, Italy, 20Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy

    Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
  • Abstract Number: 0381 • ACR Convergence 2024

    Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment

    Timothy Hahn1, George Tomlinson2, Yukiko Kimura3, Vincent Del Gaizo4, Carlos Valdes5 and Timothy Beukelman6, and for the CARRA FROST Investigators, 1Penn State Childrens Hospital, Hershey, PA, 2University of Toronto, Toronto, ON, Canada, 3Hackensack Meridian School of Medicine, New York, NY, 4Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 5Genentech, Davie, FL, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
  • Abstract Number: 0405 • ACR Convergence 2024

    Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial

    Ekaterina Alexeeva1, Tatiana Dvoryakovskaya2, Elena Zholobova3, Elizaveta Krekhova4, Rinat Raupov5, Daria Bukhanova6, Alina Egorova6, Sofia Kuzkina6, Mikhail Samsonov6, Irina Nikishina7 and Mikhail Kostik5, 1National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 2National Medical Research Center of Children's Health, Moscow, Russia, 3Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 4National Medical Research Centre for Children's Health, Moscow, Russia, 5Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 6R-Pharm, Moscow, Russia, 7V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
  • Abstract Number: 1117 • ACR Convergence 2024

    JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review

    Nuria Barroso Garcia1, Lara Sanchez Bilbao2, Jose Luis Martin Varillas3, Vanesa Calvo-Rio4, Mar Esteban Ortega5, Santiago muñoz Fernández5, Jose Luis álvarez Vega6, Emma Beltran Catalan7, Vega Jovani8, Olga Maiz Alonso9, Raúl Veroz González10, Carmen Alvarez Reguera11, Rosalia Demetrio Pablo12 and Ricardo Blanco-Alonso13, 1Rheumatology, Hospital Regional Universitario, Universidad de Málaga UMA, Málaga, Spain, Malaga, Spain, 2Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology. Hospital de Laredo. IDIVAL, Immunopathology Group. Laredo, Spain, Santander, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Rheumatology and Ophthalmology. Hospital Infanta Sofía, Madrid. Spain, Madrid, Spain, 6Rheumatology. Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, Badajoz, Spain, 7Rheumatology. Hospital del Mar. Barcelona, Spain, Barcelona, Spain, 8National Health system, Alicante, Spain, 9Rheumatology. Hospital de Donostia. San Sebastián, Spain, San Sebastián, Spain, 10Hospital Mérida, Badajoz, Spain, 11Hospital Universitario Marqués de Valdecilla, Santander, Spain, 12Rheumatology and Ophthalmology. Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group. Santander. Spain, Santander, Spain, 13Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Non-infectious uveitis refractory to conventional immunosuppressants and even biologic therapy can lead to severe ocular conditions. Janus Kinase inhibitors (JAKINIBs) appear to be effective…
  • Abstract Number: 2192 • ACR Convergence 2024

    Utilizing Electronic Health Record Pre-Consultation Data to Create a Predictive Algorithm for Diagnosis of Chronic Pediatric Rheumatic Conditions

    Kendra Lauer1, Kyla Driest2, Laura Pratt3 and Alysha Taxter2, 1Nationwide Children's Hospital, Dublin, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH

    Background/Purpose: With the current workforce shortage, wait times for initial consultation with pediatric rheumatology are lengthy and many referrals do not result in a rheumatic…
  • Abstract Number: 0382 • ACR Convergence 2024

    Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation

    Ilaria Maccora1, Mariia Pavlenko2, Jackeline Rodriguez-Smith3, Amy Cassedy4, Mekibib Altaye5, hermine brunner6, Alexandra Duell5, Alexei Grom5, Theresa Hennard7, Virginia Miraldi Utz5, Najima Mwase5, Megan Quinlan-Waters5, grant schulert5, Alyssa Sproles8, Jessica Shantha9, Sunil K Srivastava10, Sherry Thornton8, Steven Yeh11 and sheila Angeles-Han12, 1?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 2Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, 4Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 7Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 8Cincinnati Children's Hospital, Cincinnati, 9UCSF/Proctor Foundation, San Francisco, IL, 10Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, 11Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, 12Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
  • Abstract Number: 0406 • ACR Convergence 2024

    Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis

    Anna Costello1, Cassandra Muir1, Rui Xiao2, Pamela Weiss3 and Irit Rasooly1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy, prevents accrual of joint damage, and improves outcomes. Data regarding the diagnostic…
  • Abstract Number: 1233 • ACR Convergence 2024

    Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis

    Aviya Lanis1, Emily Steelquist2, Christian Lood3 and Susan Shenoi4, 1Seattle Children's Hospital, Seattle, WA, 2OHSU, Portland, OR, 3Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, 4Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) have impaired quality of life and increased rates of anxiety and depression (15-65%), even…
  • Abstract Number: 2529 • ACR Convergence 2024

    Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project

    Dori Abel1, Kirsten Spichiger2, Megan Roman2, William Baar2, Claire O'Malley2, Jay Mehta1, Terri Al'Hadi2, Kerry Ferraro3, Denique Butler2, Asia Wilson-Sanders2, Catherine Lewis2, Danielle Dodson4 and Jon Burnham1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, 3JIA parent and CHOP volunteer, Lower Gwynedd, PA, 4The Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
  • Abstract Number: 0383 • ACR Convergence 2024

    Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State

    Ilaria Maccora1, hermine brunner2, Mekibib Altaye3, Alexandra Duell3, Wendy Haffey4, Megan Quinlan-Waters3, Alyssa Sproles5, Sherry Thornton5, Virginia Miraldi Utz3, Kenneth Greis4 and sheila Angeles-Han6, 1?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 2Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, 5Cincinnati Children's Hospital, Cincinnati, 6Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
  • Abstract Number: 0407 • ACR Convergence 2024

    Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India

    Lekshmi Minikumari Rahulan1, Able Lawrence2 and Amita Aggarwal3, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 2SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Familial aggregation of autoimmune disease as well as co-occurrence of multiple autoimmune diseases in one individual is known and it suggests a shared genetic…
  • Abstract Number: 1235 • ACR Convergence 2024

    Rheum to Grow: Supporting Young Adults with Childhood-Onset Rheumatic Disease in Their Transition to Adult Care

    Cindy Chiu1, Sadie Van den Bogaerde2, Maya Swaminathan3, Rebecca Sadun4 and Thomason Jenna1, 1University of Washington, Division of Rheumatology, Seattle, WA, 2University of Washington, Seattle, WA, 3MultiCare, Newcastle, WA, 4Duke University, Durham, NC

    Background/Purpose: Transitional care for patients with childhood-onset rheumatic disease is essential, as this transition is known to be a high-risk time for medication nonadherence, lapses…
  • Abstract Number: 2570 • ACR Convergence 2024

    Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease

    Esraa Eloseily1, Autumn Clark1, Min-Lee Chang2, Mary Ellen Riordan3, Alan Russell4, Marc Natter5, Scott Canna6, Sherry Thornton7, Yukiko Kimura8 and grant schulert1, and CARRA FROST Investigators and the CARRA Registry SJIA-LD Cohort Investigators, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, 3Hackensack University Medical Center, Westwood, NJ, 4Duke Clinical Research Institute, Durham, NC, 5Boston Children's Hospital, Boston, MA, 6Children's Hospital of Philadelphia, Philadelphia, PA, 7Cincinnati Children's Hospital, Cincinnati, 8Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging life-threatening disease with urgent unmet knowledge gaps. This study compares the clinical…
  • Abstract Number: 0384 • ACR Convergence 2024

    Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study

    Corey J. Bishop1, Edwin Lam2, Sophia G. Liva3, Jocelyn H. Leu2, Amy S. Paller4, Lucia Z. Diaz5, Laura Wine Lee6, Cory Rubin7, Ruy Carrasco8, Lisa Imundo9, Azadeh Majlessi10, Katherine Berezny1, Kathleen G. Lomax1, Valerie Smith1, Renping Zhang1 and hermine brunner11, 1Janssen Research & Development, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 4Northwestern University, Feinberg School of Medicine, Chicago, IL, 5Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, 6Medical University of South Carolina, Charleston, SC, 7Michigan Dermatology Institute, Waterford, MI, 8Pediatric Rheumatology Consultants of Austin, Austin, TX, 9Columbia University Medical Center, New York, NY, 10Newport Huntington Medical Group, Huntington Beach, CA, 11Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
  • Abstract Number: 0408 • ACR Convergence 2024

    Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study

    Michael Matt1, Mariana Correia Marques2, Sabrina Fuehner3, Lexi Auld1, George Tomlinson4, Michael Ombrello5, Yukiko Kimura6, Christoph Kessel7 and grant schulert1, and the CARRA FROST Investigators, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2National Institutes of Health, Bethesda, MD, 3Universitaetsklinikum Muenster, Muenster, Germany, 4University of Toronto, Toronto, ON, Canada, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 6Hackensack Meridian School of Medicine, New York, NY, 7University Hospital Muenster, Muenster, Germany

    Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…
  • 1
  • 2
  • 3
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology